ClearPoint Neuro Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$53.1Mnext fiscal year
FY EPS (est.)
-$1.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly12.1MTarget: 52000000 - 56000000
Activated Installed Base (Global Centers) Quarterly175.0Target: 200+
Active Biopharma Partners Quarterly60.0Target: 60+
Gross Margin Quarterly64.0%
Watch Items
- IRRAflow Integration and SynergiesTrigger: Slower-than-expected commercial adoption or persistent high operating expensesAction: Re-evaluate commercial headcount allocation and cost-synergy timelines in the second half of 2026.
- Biopharma Partner Clinical Trial ProgressTrigger: Late-stage clinical trial failures or regulatory delays for partnered gene/cell therapiesAction: Adjust long-term recurring disposable revenue projections and reassess platform viability.
- Cash Burn Rate and RunwayTrigger: Quarterly operational cash burn exceeding $8.0 million without corresponding revenue growthAction: Review capital expenditure plans, slow down preclinical CRO facility expansion, or draw down remaining Oberland Capital note facility.
Research as of 19 Jun 2026